Member Info for DugWalker

Anyone thinking of buying or selling a stakeholding in OBD should read the excellent article that can be found here;

Https://www.yellowstoneadvisory.com/post/oxford-biodynamics-funding-provides-platform-for-future-growth

The optics should reflect on the fact he bought 5 times the amount he had sold just a few months ago and he owns 14% of the company. His selling £50k worth of shares is not something I'm losing sleep over.

Whilst the potential for a buyout exists I'd rather OBD continues to trade under its own steam as the income streams from CIRT and PSE will be transformational for the company.

glad to hear you're good kingalf.

earlier this year i went through a spell where i was waking up in a sweat and needing a ****. as i'm no spring chicken anymore, i decided to have a chat with my gp. this lead to me receiving a psa (normal) and a digit where digits should not tread. not nice.

i have learned a lot from this thread and had i been aware of the risk of a biopsy and the potential side effects i'm not so sure i'd have initiated what i thought was a sensible, precautionary health check.

the pse test is a god send to all men 'of an age'. there is nothing remotely comparable in terms of accuracy, sensitivity and specificity.

obd seem to be at the forefront in the field of applied 3 d genomics. they are currently working on diagnostics for mnd amongst other challenging diseases. this company is going far.

I think folks are going to be surprised by how soon the test becomes adopted by the NHS. Yes there are processes to go through but OBD are fully aware of existing options to speed things along.

He bought 440,000 back in January at 13p. That took him to 14.06% of the share register. He took a wee bit of profit today, still holds 14.01% ofbthe share register and still owns more of the company than he did at the start of this year.

Tree shake again to hoover up stop losses and timid PI's.

2nd day in a row MMs have actively marked the price down even when bought value has exceded sold value.

Chairman walking away as talk of acquisitions emerges. Still no sign of the pro.ised new contracts. Becoming concerning.

Shares never go up In a straight line. Following a few days of stellar rises the SP is now consolidating before rising further. Could baseless inferences of something being wrong ("just can't fathom it") be coming from folks looking for a lower entry point.

Derampers you got to laugh.

3"in the uk, the london stock exchange is open from 08:00 until 16:30 and that’s when most big banks and retail investors will be buying and selling shares.

but some people do trade the market outside of these hours. this is usually referred to as after-hours trading."

https://************/dictionary/after-hours-trading#:~:text=in%20the%20uk%2c%20the%20london,to%20as%20after%2dhours%20trading.

Google SP chart suggests bid is back up to 39.3 in after hours trading.

Some folks are utter bafoons and seem comfortable providing regular public confirmation.

If she wants to chunter about how survival rates not justifying any prioritising of prostate cancer perhaps she should pause to consider its prevalence relative to.othet male cancers. 1 in 8 men get this but that's OK because only 15% of them die within 5 years.

Total turnip head.

In the UK 100000 men per year have a prostate biopsy. The cost to the NHS including initial consultations, cost of operating theatre, support staff (nurses, anesthetist, anesthetics, pain relief, pathology, accommodation, general overheads and follow up) must be many thousands per case. Let's assume a ludicrously modest cost differential to the PSE of £5k per biopsy. If 50,0000 of those biopsies were deemed unnecessary by virtue of a PSE test and each unnecessary procedure saves the NHS 5k, then the annual saving would be 250 million per annum. That's just based on people having the biopsy. It doesn't account for the thousands of MRI procedures undertaken by the current diagnostic process.

When you cite a case of someone being misdiagnosed by a PSA test, having discussions with a consultant, being operated on, having a succession of follow up appointments only to be given the all clear post biopsy you are making an excellent case as to why the PSE test will replace such a calamitous and costly process.

Absurd tree shake this morning. MM's happily hoovering up stop losses and scaring the timid. There have been more buys than sells today! A 10% drop in SP cannot be justified and this will turn back up soon.

@Slacker.

Yep 1300 tests in the US gets OBD £1 million in revenue.

That should only be days away. You really don't want to be out of this share when the RNS drops.

With a 5 day turnaround to get your test results and the cost covered by insurance, I wonder if the US can muster a group of 1300 men that want the test right now in order to avoid a biopsy?

If so the RNS announcing the first £1 million in sales won't be long in arriving.

MM 's share hunting this morning. SP down when bought value is twice the sold value! It's got to bounce back into the 40's

Don't ignore him, report him.

Everytime he posts something defamatory about companies/regulators/companies (most of his posts).

Everytime he posts misleading information relating to the science behind the test (frequently).